Landmark Month Sees Second Gene Therapy Approved and Other Advances

RxC International Gene Therapy Newsletter

October was a landmark month for gene therapies with the approval of the second-ever gene therapy in the US, Yescarta (axicabtagene ciloleucel) from Kite and Gilead.  The prior approval of Novartis’ Kymriah is more proof that gene therapies are set to shake up the pharma industry.  Gene therapies saw other wins as Luxturna, Spark’s treatment for Leber congenital amaurosis, received the FDA’s recommendation for approval and Bluebird Bio’s interim data report for its gene therapy Lenti-D to treat cerebral adrenoleukodystrophy showed promising results.


 

Planning for Gene Therapy Success

 
RxC Gene Therapy

With clinical trial successes bringing gene therapy closer to FDA approval and eventual commercialization, it's critical for companies developing gene therapies to understand the marketplace and plan accordingly.  

RxC International has put together a white paper containing important information on the current state of gene therapies, companies driving the market forward, and what to consider when beginning the process of commercialization.

 

Gene Therapy Articles and Other Resources